SI2200700T1 - Nova protitelesa - Google Patents

Nova protitelesa

Info

Publication number: SI2200700T1
Authority: SI; Slovenia
Prior art keywords: novel antibodies; antibodies; novel
Prior art date: 2007-09-26

Application number

SI200831589T

Other languages

English (en)

Inventor

Wei-Ching Liang

Gregory D. Plowman

Yan Wu

Weilan Ye

Original Assignee

Genentech, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-26

Filing date

2008-09-25

Publication date

2016-04-29

2008-09-25 Application filed by Genentech, Inc. filed Critical Genentech, Inc.

2016-04-29 Publication of SI2200700T1 publication Critical patent/SI2200700T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Dermatology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Rheumatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SI200831589T 2007-09-26 2008-09-25 Nova protitelesa SI2200700T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US97547107P	2007-09-26	2007-09-26
EP08834260.5A EP2200700B1 (en)	2007-09-26	2008-09-25	Novel antibodies
PCT/US2008/077622 WO2009042746A1 (en)	2007-09-26	2008-09-25	Novel antibodies

Publications (1)

Publication Number	Publication Date
SI2200700T1 true SI2200700T1 (sl)	2016-04-29

Family

ID=40329277

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200831589T SI2200700T1 (sl)	2007-09-26	2008-09-25	Nova protitelesa

Country Status (22)

Country	Link
US (3)	US7973138B2 (sl)
EP (1)	EP2200700B1 (sl)
JP (1)	JP2011501656A (sl)
KR (1)	KR20100065162A (sl)
CN (1)	CN101888878B (sl)
AR (1)	AR066170A1 (sl)
AU (1)	AU2008304452B2 (sl)
BR (1)	BRPI0816049A2 (sl)
CA (1)	CA2698609A1 (sl)
CL (1)	CL2008002856A1 (sl)
CO (1)	CO6260094A2 (sl)
DK (1)	DK2200700T3 (sl)
HR (1)	HRP20160308T1 (sl)
HU (1)	HUE027911T2 (sl)
MX (1)	MX2010003325A (sl)
MY (1)	MY151191A (sl)
NZ (1)	NZ584838A (sl)
PE (1)	PE20091029A1 (sl)
RU (1)	RU2490277C2 (sl)
SI (1)	SI2200700T1 (sl)
TW (1)	TWI547503B (sl)
WO (1)	WO2009042746A1 (sl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2200700T1 (sl)	2007-09-26	2016-04-29	Genentech, Inc.	Nova protitelesa
JP6051048B2 (ja) *	2009-03-25	2016-12-21	ジェネンテック，インコーポレイテッド	新規な抗α５β１抗体及びその使用
CA2665956A1 (en) *	2009-05-07	2010-11-07	Samir Patel	Combination treatment for ocular diseases
AR076662A1 (es)	2009-05-08	2011-06-29	Genentech Inc	Anticuerpos anti-egfl7 humanizados y metodos de uso de los mismos
US8956600B2 (en)	2009-08-10	2015-02-17	Taiwan Liposome Co. Ltd.	Ophthalmic drug delivery system containing phospholipid and cholesterol
WO2012154983A2 (en)	2011-05-10	2012-11-15	Biocare Medical, Llc	Systems and methods for anti-pax8 antibodies
US20130058926A1 (en) *	2011-08-30	2013-03-07	Shiseido Company, Ltd.	Method for alleviating and/or preventing skin reddening
US10316103B1 (en)	2012-03-30	2019-06-11	Biocare Medical, Llc	Systems and methods for anti-Uroplakin III antibodies
US9494597B2 (en) *	2012-04-02	2016-11-15	Ab Biosciences, Inc.	Human control antibodies and uses therefor
DK2847231T3 (da)	2012-05-10	2019-10-14	Bioatla Llc	Multispecifikke monoklonale antistoffer
EP2900265B1 (en)	2012-09-27	2018-05-30	Biocare Medical, LLC	Anti-uroplakin ii antibodies systems and methods
US10429390B2 (en)	2012-12-18	2019-10-01	Biocare Medical, Llc	Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
US10023638B2 (en)	2012-12-26	2018-07-17	Oncosynergy, Inc.	Anti-integrin β1 antibody compositions and methods of use thereof
EP2948472B1 (en)	2013-01-23	2019-05-22	Syddansk Universitet	Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors
WO2014122143A1 (en) *	2013-02-05	2014-08-14	Engmab Ag	Method for the selection of antibodies against bcma
EP2962113B1 (en)	2013-02-28	2019-04-03	Biocare Medical, LLC	Anti-p40 antibodies systems and methods
WO2015051320A2 (en)	2013-10-03	2015-04-09	Biocare Medical, Llc	Anti-sox10 antibody systems and methods
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
KR20180104635A (ko)	2015-12-30	2018-09-21	코디악 사이언시스 인코포레이티드	항체 및 이의 접합체
AU2019227997A1 (en)	2018-03-02	2020-09-24	Kodiak Sciences Inc.	IL-6 antibodies and fusion constructs and conjugates thereof
CN108693004B (zh) *	2018-05-24	2020-08-04	中国农业科学院农业质量标准与检测技术研究所	一种检测菜籽粕中是否掺杂抗生素滤渣的方法
KR20220047536A (ko) *	2019-04-01	2022-04-18	레이크파르마, 인코퍼레이티드	면역반응의 조절 및 질병의 치료를 위한 btla-결합(cd272) 항체
EP4041312A4 (en)	2019-10-10	2023-12-20	Kodiak Sciences Inc.	METHOD FOR TREATING AN EYE DISORDER
CN114688461A (zh) *	2020-12-31	2022-07-01	青岛海尔施特劳斯水设备有限公司	一种漏水检测方法及系统
CN113133431A (zh) *	2021-02-25	2021-07-20	中南大学	慢性高眼压合并长眼轴动物模型的建立方法、模型及应用
CN114073996B (zh) *	2021-11-24	2023-04-14	中山大学	一种嵌套式微井阵列芯片及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5540933A (en)	1985-05-31	1996-07-30	La Jolla Cancer Research Foundation	Isolation and use of fibronectin receptor
EP0330506A3 (en)	1988-02-26	1990-06-20	Dana Farber Cancer Institute	Vla proteins
US20020146410A1 (en)	1992-05-22	2002-10-10	Helmut Eckert	Monoclonal antibodies and their use
US5627263A (en)	1993-11-24	1997-05-06	La Jolla Cancer Research Foundation	Integrin-binding peptides
US5981478A (en)	1993-11-24	1999-11-09	La Jolla Cancer Research Foundation	Integrin-binding peptides
SI0719859T1 (sl) *	1994-12-20	2003-12-31	Merck Patent Gmbh	Monoklonsko protitelo proti alfa-v-integrinu
BR9907218A (pt)	1998-01-23	2000-10-24	Merck Patent Gmbh	Anticorpo monoclonal anti alfav-integrina e seu uso para inibir a fixação de alfav-beta6-integrina à fibronectina
WO1999058139A2 (en)	1998-05-08	1999-11-18	The Regents Of The University Of California	Methods for detecting and inhibiting angiogenesis
US6852318B1 (en)	1998-05-08	2005-02-08	The Regents Of The University Of California	Methods for detecting and inhibiting angiogenesis
US6737056B1 (en) *	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
GB9909392D0 (en)	1999-04-24	1999-06-23	Imp Cancer Res Tech	Treatment, imaging and diagnosis of disease
US20040009494A1 (en)	1999-08-11	2004-01-15	Richard Murray	Novel methods of diagnosis of angiogenesis and other conditions, compositions, and the methods of screening for modulators
US20020019330A1 (en)	1999-08-11	2002-02-14	Richard Murray	Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
US20030152926A1 (en)	1999-08-11	2003-08-14	Eos Biotechnology, Inc.	Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20020015970A1 (en)	1999-08-11	2002-02-07	Richard Murray	Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
WO2001011086A2 (en)	1999-08-11	2001-02-15	Eos Biotechnology, Inc.	Methods of screening for angiogenesis modulators
US20040259152A1 (en)	2000-02-22	2004-12-23	Richard Murray	Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
CA2438030A1 (en)	2001-02-14	2002-10-10	Protein Design Labs	Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
CA2444691A1 (en)	2001-04-18	2002-10-31	Protein Design Labs, Inc.	Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
WO2002098358A2 (en)	2001-06-04	2002-12-12	Eos Biotechnology, Inc.	Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
AU2002347428A1 (en)	2001-06-18	2003-01-02	Eos Biotechnology Inc.	Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7189507B2 (en)	2001-06-18	2007-03-13	Pdl Biopharma, Inc.	Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040076955A1 (en)	2001-07-03	2004-04-22	Eos Biotechnology, Inc.	Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20040033495A1 (en)	2001-08-03	2004-02-19	Eos Biotechnology, Inc.	Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20030124579A1 (en)	2001-09-05	2003-07-03	Eos Biotechnology, Inc.	Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CA2459219A1 (en)	2001-09-17	2003-03-27	Protein Design Labs, Inc.	Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US20070042360A1 (en)	2001-09-17	2007-02-22	Eos Biotechnology, Inc.	Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003042661A2 (en)	2001-11-13	2003-05-22	Protein Design Labs, Inc.	Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20030232350A1 (en)	2001-11-13	2003-12-18	Eos Biotechnology, Inc.	Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20060241067A1 (en)	2002-06-25	2006-10-26	Varner Judith A	Methods For inhibiting angiogenesis, cell migration, cell adhesion, and cell survival
JP4667873B2 (ja)	2002-07-16	2011-04-13	アベンティス・ファーマシューティカルズ・インコーポレイテッド	α５β１およびその細胞生存経路を調節する能力
US20040253606A1 (en)	2002-11-26	2004-12-16	Protein Design Labs, Inc.	Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
RU2346701C2 (ru) *	2002-11-26	2009-02-20	ПиДиЭл БАЙОФАРМА ИНК.	ХИМЕРНЫЕ И ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ ИНТЕГРИНА α5β1, КОТОРЫЕ МОДУЛИРУЮТ АНГИОГЕНЕЗ
US7276589B2 (en)	2002-11-26	2007-10-02	Pdl Biopharma, Inc.	Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7285268B2 (en)	2002-11-26	2007-10-23	Pdl Biopharma, Inc.	Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
WO2004089988A2 (en)	2003-04-03	2004-10-21	Protein Design Labs, Inc	Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
JP4857259B2 (ja) *	2004-03-24	2012-01-18	アボットバイオセラピューティクスコーポレイション	癌細胞増殖を阻害するための抗α５β１抗体の使用
US20060008415A1 (en)	2004-06-25	2006-01-12	Protein Design Labs, Inc.	Stable liquid and lyophilized formulation of proteins
PL1819359T3 (pl)	2004-12-09	2015-08-31	Janssen Biotech Inc	Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie
JP2009516729A (ja)	2005-11-23	2009-04-23	アストラゼネカアクチボラグ	Ｌ−フェニルアラニン誘導体
JP2009516730A (ja)	2005-11-23	2009-04-23	アストラゼネカアクチボラグ	Ｌ−アラニン誘導体
EP1984330A1 (en)	2006-02-09	2008-10-29	AstraZeneca AB	Chemical compounds
KR101454491B1 (ko) *	2006-03-21	2014-10-29	제넨테크, 인크.	알파5베타1 길항제를 포함하는 조합 치료법
EP2032605A2 (en)	2006-05-24	2009-03-11	Bayer Schering Pharma Aktiengesellschaft	HIGH AFFINITY HUMAN AND HUMANIZED ANTI-alpha5ß1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY
SI2200700T1 (sl)	2007-09-26	2016-04-29	Genentech, Inc.	Nova protitelesa
US8039596B2 (en)	2008-02-05	2011-10-18	Bristol-Myers Squibb Company	Alpha 5-beta 1 antibodies and their uses

2008
- 2008-09-25 SI SI200831589T patent/SI2200700T1/sl unknown
- 2008-09-25 CA CA2698609A patent/CA2698609A1/en not_active Abandoned
- 2008-09-25 US US12/237,640 patent/US7973138B2/en not_active Expired - Fee Related
- 2008-09-25 CL CL2008002856A patent/CL2008002856A1/es unknown
- 2008-09-25 WO PCT/US2008/077622 patent/WO2009042746A1/en active Application Filing
- 2008-09-25 AR ARP080104170A patent/AR066170A1/es unknown
- 2008-09-25 TW TW097136935A patent/TWI547503B/zh not_active IP Right Cessation
- 2008-09-25 PE PE2008001669A patent/PE20091029A1/es not_active Application Discontinuation
- 2008-09-25 MX MX2010003325A patent/MX2010003325A/es active IP Right Grant
- 2008-09-25 CN CN200880117702.0A patent/CN101888878B/zh not_active Expired - Fee Related
- 2008-09-25 DK DK08834260.5T patent/DK2200700T3/en active
- 2008-09-25 JP JP2010527128A patent/JP2011501656A/ja active Pending
- 2008-09-25 BR BRPI0816049A patent/BRPI0816049A2/pt not_active IP Right Cessation
- 2008-09-25 HU HUE08834260A patent/HUE027911T2/en unknown
- 2008-09-25 RU RU2010116184/10A patent/RU2490277C2/ru not_active IP Right Cessation
- 2008-09-25 AU AU2008304452A patent/AU2008304452B2/en not_active Ceased
- 2008-09-25 KR KR1020107006513A patent/KR20100065162A/ko active IP Right Grant
- 2008-09-25 NZ NZ584838A patent/NZ584838A/xx not_active IP Right Cessation
- 2008-09-25 EP EP08834260.5A patent/EP2200700B1/en active Active
- 2008-09-25 MY MYPI20101284 patent/MY151191A/en unknown
2010
- 2010-03-19 CO CO10033130A patent/CO6260094A2/es active IP Right Grant
2011
- 2011-05-20 US US13/112,839 patent/US8840887B2/en not_active Expired - Fee Related
- 2011-05-20 US US13/112,833 patent/US9284376B2/en not_active Expired - Fee Related
2016
- 2016-03-23 HR HRP20160308TT patent/HRP20160308T1/hr unknown

Also Published As

Publication number	Publication date
US8840887B2 (en)	2014-09-23
CO6260094A2 (es)	2011-03-22
EP2200700A1 (en)	2010-06-30
RU2490277C2 (ru)	2013-08-20
PE20091029A1 (es)	2009-08-19
MY151191A (en)	2014-04-30
TWI547503B (zh)	2016-09-01
CA2698609A1 (en)	2009-04-02
CN101888878B (zh)	2014-05-21
RU2010116184A (ru)	2011-11-10
CN101888878A (zh)	2010-11-17
HRP20160308T1 (hr)	2016-04-22
AU2008304452A1 (en)	2009-04-02
HUE027911T2 (en)	2016-11-28
EP2200700B1 (en)	2016-01-13
US20120148572A1 (en)	2012-06-14
BRPI0816049A2 (pt)	2019-09-24
US20090098112A1 (en)	2009-04-16
CL2008002856A1 (es)	2009-01-16
WO2009042746A1 (en)	2009-04-02
KR20100065162A (ko)	2010-06-15
US9284376B2 (en)	2016-03-15
AR066170A1 (es)	2009-07-29
US7973138B2 (en)	2011-07-05
TW200924794A (en)	2009-06-16
JP2011501656A (ja)	2011-01-13
US20120156129A1 (en)	2012-06-21
NZ584838A (en)	2012-08-31
AU2008304452B2 (en)	2014-01-16
DK2200700T3 (en)	2016-04-11
MX2010003325A (es)	2010-04-09

Publication	Publication Date	Title
SI2200700T1 (sl)	2016-04-29	Nova protitelesa
GB0708002D0 (en)	2007-06-06	Antibodies
PL2146745T3 (pl)	2015-11-30	Pięcioswoiste przeciwciało
EP2138576A4 (en)	2011-02-23	ANTI-CLAUDIN-4 ANTIBODY
IL229512A (en)	2015-07-30	Anti-vegf antibodies
EP2241578A4 (en)	2012-09-12	ANTI-CLDN6 ANTIBODIES
ZA200906345B (en)	2010-11-24	Anti-sclerostin antibodies
PT2195026E (pt)	2014-03-31	Anticorpos anti-esclerostina
HK1146728A1 (en)	2011-07-08	Modified antibody constant region
EP2172483A4 (en)	2010-08-04	ANTI-MUC17 ANTIBODY
GB0821100D0 (en)	2008-12-24	Antibodies
GB0702888D0 (en)	2007-03-28	Novel Antibodies
PL2011869T3 (pl)	2014-11-28	Nowe przeciwciało anty-CD98
EP2337798A4 (en)	2012-10-24	BSA-SPECIFIC ANTIBODIES
GB0718737D0 (en)	2007-11-07	Antibodies
IL205073A0 (en)	2010-11-30	Anti-bst2 antibody
IL207581A0 (en)	2010-12-30	Anti-tyrp1 antibodies
ZA201007976B (en)	2012-02-29	Anti-pirb antibodies
GB0818356D0 (en)	2008-11-12	Antibodies
GB0911770D0 (en)	2009-08-19	Antibody
GB0724185D0 (en)	2008-01-23	Antibodies
GB0806230D0 (en)	2008-05-14	Antibodies
GB0823562D0 (en)	2009-01-28	Antibodies
GB0606276D0 (en)	2006-05-10	Antibodies
GB0607376D0 (en)	2006-05-24	Antibodies